CNMD vs. INMD, SLNO, LIVN, BLFS, ITGR, TMDX, MASI, RXST, VERA, and ASTH
Should you be buying CONMED stock or one of its competitors? The main competitors of CONMED include InMode (INMD), Soleno Therapeutics (SLNO), LivaNova (LIVN), BioLife Solutions (BLFS), Integer (ITGR), TransMedics Group (TMDX), Masimo (MASI), RxSight (RXST), Vera Therapeutics (VERA), and Astrana Health (ASTH). These companies are all part of the "medical" sector.
InMode (NASDAQ:INMD) and CONMED (NYSE:CNMD) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.
InMode currently has a consensus target price of $32.80, indicating a potential upside of 72.63%. CONMED has a consensus target price of $107.86, indicating a potential upside of 44.64%. Given CONMED's higher probable upside, equities research analysts clearly believe InMode is more favorable than CONMED.
InMode has higher earnings, but lower revenue than CONMED. InMode is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.
InMode received 132 more outperform votes than CONMED when rated by MarketBeat users. Likewise, 75.12% of users gave InMode an outperform vote while only 42.37% of users gave CONMED an outperform vote.
68.0% of InMode shares are held by institutional investors. 6.9% of InMode shares are held by insiders. Comparatively, 6.8% of CONMED shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
InMode has a net margin of 38.84% compared to InMode's net margin of 6.53%. CONMED's return on equity of 26.15% beat InMode's return on equity.
InMode has a beta of 2.2, suggesting that its share price is 120% more volatile than the S&P 500. Comparatively, CONMED has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500.
In the previous week, InMode had 2 more articles in the media than CONMED. MarketBeat recorded 7 mentions for InMode and 5 mentions for CONMED. CONMED's average media sentiment score of 0.99 beat InMode's score of 0.55 indicating that InMode is being referred to more favorably in the media.
Summary
InMode beats CONMED on 13 of the 18 factors compared between the two stocks.
Get CONMED News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CNMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
